US biotech Axsome Therapeutics (Nasdaq: AXSM) is set to close 2019 with a share price worth around 40 times more than its value at the start of the year.
The CNS specialist topped off a stellar year by presenting Phase III data on AXS-07 (meloxicam and rizatriptan) its oral, multi-mechanistic investigational medicine for the acute treatment of migraine.
AXS-07 met the two regulatory co-primary endpoints and significantly improved migraine pain and most bothersome symptoms as compared to placebo in the MOMENTUM trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze